SERPINA1 and chronic obstructive pulmonary disease: Among these, alpha-1 antitrypsin (AAT) deficiency remains the most established endotype biomarker and treatable trait in COPD, with serum AAT levels serving to identify patients eligible for augmentation therapy [28].